A Phase III Clinical Trial of Bevacizumab with IV versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma NCI-Supplied Agent(s): Bevacizumab
Principal Investigator
Joan Walker, MD
Status
Terminated
Disease Site
Gynecologic [GY]
Ovarian
Phase
III
Developmental Therapeutics
No
Primary Objective
To determine if one or both of the proposed intraperitoneal chemotherapy regimens improves the progression-free survival (PFS) event rate compared to standard intravenous chemotherapy for first-line treatment of patients diagnosed with advanced stage ovarian, peritoneal or fallopian tube cancer.
Patient Population
Patients diagnosed with advanced stage ovarian, peritoneal or fallopian tube cancer.
Target Accrual
1500
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.